SPRO - Spero Therapeutics Inc Stock Price, Fair Value and News

1.44USD+0.03 (+2.13%)Market Closed

Market Summary

USD1.44+0.03

Market Closed

2.13%

SPRO Stock Price

View Fullscreen

SPRO RSI Chart

SPRO Valuation

Market Cap

76.1M

Price/Earnings (Trailing)

3.25

Price/Sales (Trailing)

0.69

Price/Free Cashflow

-5.36

SPRO Price/Sales (Trailing)

SPRO Profitability

Return on Equity

24.32%

Return on Assets

13.96%

Free Cashflow Yield

-18.66%

SPRO Fundamentals

SPRO Revenue

Revenue (TTM)

111.0M

Rev. Growth (Yr)

347.9%

Rev. Growth (Qtr)

-87.4%

SPRO Earnings

Earnings (TTM)

23.4M

Earnings Growth (Yr)

4.5%

Earnings Growth (Qtr)

-124.75%

Breaking Down SPRO Revenue

Last 30 days

6.8%

Last 90 days

-2.7%

How does SPRO drawdown profile look like?

SPRO Financial Health

Current Ratio

3.35

SPRO Investor Care

Shares Dilution (1Y)

2.69%

Diluted EPS (TTM)

0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	111.0M	0	0	0
2023	53.5M	54.2M	77.7M	103.8M
2022	13.0M	9.9M	8.8M	53.5M
2021	14.9M	18.4M	17.4M	18.3M
2020	12.1M	11.7M	11.1M	9.3M
2019	10.5M	12.2M	16.2M	18.1M
2018	3.0M	3.2M	3.3M	4.0M
2017	663.7K	992.3K	1.3M	2.0M
2016	0	0	0	335.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Satyavrat Shukla C.F.A.
WEBSITE	https://sperotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	35

Spero Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Spero Therapeutics Inc? What does SPRO stand for in stocks?

SPRO is the stock ticker symbol of Spero Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spero Therapeutics Inc (SPRO)?

As of Thu Jul 25 2024, market cap of Spero Therapeutics Inc is 76.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRO stock?

You can check SPRO's fair value in chart for subscribers.

Is Spero Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SPRO is over valued or under valued. Whether Spero Therapeutics Inc is cheap or expensive depends on the assumptions which impact Spero Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRO.

What is Spero Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, SPRO's PE ratio (Price to Earnings) is 3.25 and Price to Sales (PS) ratio is 0.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRO PE ratio will change depending on the future growth rate expectations of investors.